Table 1.

Patients’ and primary tumor’s characteristics

Total	48a
Mean age, years (SD)	58.5 (±11.0)
Range	36-75
Tumor size
pT1a-c	14 (29.2%)
pT2-4	34 (70.8%)
Lymph node status
Node negative	12 (25.0%)
Node positive (pN1-3)	35 (72.9%)
pNx	1 (2.1%)
Grading
G1-2	27 (56.2%)
G3	21 (43.8%)
Estrogen receptor status b
ER positive	30 (62.5%)
ER negative	18 (37.5%)
Progesterone receptor statusc
PR positive	25 (52.1%)
PR negative	23 (47.9%)
HER2 status
negative	36 (75.0%)
positive	11 (22.9%)
unknown	1 (2.1%)
Menopausal status
Premenopausal	15 (31.3%)
Postmenopausal	33 (68.7%)
Primary operation
Breast conservative	30 (62.5%)
Mastectomy	18 (37.5%)
Systemic therapy
Chemotherapy-FECd-DOCe	21 (43.8%)
Chemotherapy-FEC-DOC Gemf	27 (56.2%)

^aNumber of patients (percentage); ^bER estrogen receptor; ^cPR progesterone receptor; ^dFEC fluorouracil-epirubicin-cyclophosphamide; ^eDOC docetaxel; ^fGem gemcitabine